Maryland is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
NCT04588077
Recruiting
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
Register for Updates
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
NCT03808922
Recruiting
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Gender:
ALL
Ages:
All
Trial Updated:
11/18/2024
Locations: University of Maryland, Baltimore, Maryland
Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
NCT02854033
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
11/18/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Register for Updates
Reducing Vertigo Associated With MRI Machines
NCT06062368
Recruiting
Vertigo, dizziness, and imbalance are commonly reported by patients and technologists when near high-field strength magnets (\>4 Tesla, T) used for magnetic resonance imaging (MRI) (1-5) Prior research from the investigators has established that the mechanism is likely a Lorentz force occurring in the inner ear, as a result of interactions with normal electrical currents in the inner ear and the strong static magnetic field of the MRI machine. The investigators have recently developed preliminar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Vertigo, Dizziness
Register for Updates
Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
NCT05792722
Recruiting
The purpose of this clinical trial is to determine if prostate-capsule-sparing cystectomy improves functional outcomes without comprising oncologic outcomes in male patients receiving a radical cystectomy. Patients will be randomized to one of two groups: prostate capsule-sparing radical cystectomy or nerve-sparing radical cystectomy. Patients will be monitored following standard of care guidelines and clinical data will be collected. Patients in both groups will be asked to complete an erectile... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Bladder Cancer
Register for Updates
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
NCT04794699
Recruiting
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with other anticancer agents including taxanes (docetaxel, paclitaxel), or sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Solid Tumor
Register for Updates
The Myelin Disorders Biorepository Project
NCT03047369
Recruiting
The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies,... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/15/2024
Locations: Kennedy Krieger Institute, Baltimore, Maryland
Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, Aicardi Goutieres Syndrome, Metachromatic Leukodystrophy, TUBB4A-Related Leukodystrophy, 4H Syndrome, Krabbe Disease, Alexander Disease, Pelizaeus-Merzbacher Disease, Adrenoleukodystrophy, Adrenomyeloneuropathy, Multiple Sulfatase Deficiency, Megalencephalic Leukoencephalopathy With Subcortical Cysts, Vanishing White Matter Disease, Cockayne Syndrome, Labrune Syndrome, ADLD, Gangliosidoses, Peroxisomal Biogenesis Disorder, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, AGS, Alexanders Leukodystrophy, AxD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, GALC Deficiency, Globoid Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, MLD, PMD, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, GM2 Gangliosidosis, BPAN, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Register for Updates
Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction
NCT06517186
Recruiting
The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treatments for heart failure.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
11/14/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
Register for Updates
Producing Increasingly Complex Themes Using Right-hemisphere Engagement (PICTURE) Implemented With Telemedicine
NCT05845047
Recruiting
The investigators propose a pilot crossover trial of 2 behavioral language treatments, with randomized order of treatments and blinded assessors, to determine if a therapy designed to stimulate right hemisphere functions (Producing Increasingly Complex Themes Using Right-hemisphere Engagement Implemented with Telemedicine - PICTURE IT; described below) is more effective in improving discourse than a published computer delivered lexical treatment (shown previously to improve naming) in subacute p... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/14/2024
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Aphasia, Stroke
Register for Updates
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
NCT04770337
Recruiting
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse even... Read More
Gender:
ALL
Ages:
9 years and above
Trial Updated:
11/14/2024
Locations: Sinai Hospital, Baltimore, Maryland
Conditions: Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Register for Updates
Peripheral Modulation of Muscle Stiffness and Spasticity
NCT03306615
Recruiting
This is a single-center, double-blind, randomized, placebo-controlled, sequential Phase II trial of human recombinant hyaluronidase injections in individuals with post-stroke upper limb muscle stiffness. The investigators will recruit 56 subjects, who will be randomized to receive either the intervention or normal saline injections (first injection), and then the intervention the participants did not receive first (second injection). All individuals will receive the treatment by the end of the s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Muscle Spasticity
Register for Updates
Achieving Cardiovascular Health Equity in Community Mental Health: Optimizing Implementation Strategies
NCT06674616
Recruiting
In this trial, the investigators will examine the uptake of the evidenced-based IDEAL Goals program, a heart disease risk reduction program, while testing different implementation strategies with our partners in Michigan and Maryland who serve persons with serious mental illness (SMI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Cardiovascular Risk Factors, Serious Mental Illness
Register for Updates